Johnson & Johnson (JNJ)
| Market Cap | 352.79B |
| Revenue (ttm) | 85.16B |
| Net Income (ttm) | 35.15B |
| Shares Out | 2.41B |
| EPS (ttm) | 13.72 |
| PE Ratio | 10.68 |
| Forward PE | 13.63 |
| Dividend | $4.96 (3.38%) |
| Ex-Dividend Date | May 20, 2024 |
| Volume | 319,048 |
| Open | 149.37 |
| Previous Close | 146.82 |
| Day's Range | 146.01 - 146.64 |
| 52-Week Range | 143.13 - 175.97 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 166.21 (+13.41%) |
| Earnings Date | Apr 16, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $166.21, which is an increase of 13.41% from the latest price.
News
PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit
MILFORD, Conn.--(BUSINESS WIRE)-- #SOC2--PBIRx, a pharmacy benefits consulting and auditing firm, sees growth from concerns over alleged fiduciary breach lawsuit against Johnson & Johnson.
Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC)
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton ...
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relati...
Illinois Jury Awards $45 Million in Mesothelioma Case Against Johnson & Johnson, Kenvue, Inc.
CHICAGO--(BUSINESS WIRE)--A jury in the Circuit Court of Cook County in Chicago found Johnson & Johnson (NYSE:JNJ) and two subsidiaries liable in the asbestos-related death of a mother and grandmother...
Cramer's Mad Dash: Johnson & Johnson
CNBC's Jim Cramer delivers his daily Mad Dash.
WHO says wider alert on contaminated J&J cough syrup 'likely'
The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children's cough syrup found in Nigeria last week, it said in an email.
What's Next For Johnson & Johnson Stock After Beating Q1 Earnings?
Johnson & Johnson (NYSE: JNJ) recently reported its Q1 results, with revenues marginally below but earnings exceeding our estimates. The company reported revenue of $21.4 billion and adjusted earnings...
J&J wins trial over Florida woman who claimed its baby powder caused her cancer
A Florida jury on Thursday concluded that Johnson & Johnson's baby powder talc product did not cause the ovarian cancer of a Florida woman who died in 2019.
Stocks on the move: UnitedHealth and Johnson & Johnson
The Investment Committee discuss some big movers in the market today.
Johnson & Johnson Amplifies MedTech Profile in Q1 Earnings
Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare. During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and fu...
Johnson & Johnson (JNJ) Shockwave Deal & Earnings Takeaways
CFRA views the newly announced $13.1B Johnson & Johnson (JNJ) shockwave deal as positive. David Toung and Sel Hardy discuss the takeaways from Johnson & Johnson's earnings.
J&J CFO on Q1 Earnings, Forecast and Product Pipeline
Johnson & Johnson CFO Joseph Wolk discusses the company's first-quarter earnings, forecast and product pipeline on Bloomberg Television. Johnson & Johnson's first-quarter drug sales narrowly outpaced ...
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--In the section titled "Full-Year 2024 Guidance", in the table, row titled "Operational Sales2,5/ Mid-point", the numbers for the April 2024 column should read: $8...
Johnson & Johnson Stock Slips After Mixed Q1 Earnings Report
Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend while narrowing full-year guidance for 2024.
Nigerian regulator: no record of child deaths from recalled J&J cough syrup
A senior official at Nigeria's drug regulator said on Tuesday that the regulator had no record of children dying from a batch of cough syrup manufactured by Johnson & Johnson which had been recalled.
J&J CFO Joseph Wolk on Q1 earnings
Johnson & Johnson CFO Joseph Wolk joins ‘Squawk Box' to discuss the company's quarterly earnings results that topped Wall Street's expectations.
Earnings turnaround for Johnson & Johnson with Q1 2024 financial results
Pharmaceutical and consumer staples titan Johnson & Johnson reported its Q1 2024 financial results before US markets opened this morning. Johnson & Johnson announced significant turnaround in its net ...
Johnson & Johnon's Q1 profit beats as sales fall slightly short of estimates
Johnson & Johnson's stock JNJ, +0.05% fell 0.4% early Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations....
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 pe...
Johnson & Johnson tops quarterly profit estimates as medical device sales jump
The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.
J&J beats first-quarter profit estimates on cancer drugs strength
Johnson & Johnson reported a first-quarter profit above Wall Street estimates on Tuesday, helped by strong sales of its cancer drugs including top-selling blood cancer treatment Darzalex.
Johnson & Johnson Reports Q1 2024 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. “Johnson & Johnson's solid first quarter performance reflects our sharpened focus an...
Mizuho's health care earnings playbook ahead of UnitedHealth, J&J results
Jared Holz, Mizuho, joins 'Fast Money' to talk what to expect from the upcoming slate of health care earnings.
Here's What To Expect From Johnson & Johnson's Q1
Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus estima...
Johnson & Johnson Reports Earnings Tuesday. What to Expect.
Pharmaceuticals firm Johnson & Johnson kicks off earnings season for the sector on Tuesday. Investors want executives to put to rest ongoing talc litigation.